Knowledge; Access. The Stockholder has such knowledge and experience in financial and business matters and has been furnished access to such information and documents concerning the Company that it is capable of evaluating the merits and risks of accepting the Purchase Price in exchange for the Shares and the other terms and conditions of this Agreement. The Stockholder has had an opportunity to ask questions and receive answers concerning the terms and conditions of this repurchase and to obtain additional information regarding the Company's plans and future prospects.
Knowledge; Access. The Shareholder has such knowledge and experience in financial and business matters and has been furnished access to such information and documents concerning the Company that it is capable of evaluating the merits and risks of accepting the Purchase Price in exchange for the Shares and the other terms and conditions of this Agreement. The Shareholder has had an opportunity to ask questions and receive answers concerning the terms and conditions of this repurchase and to obtain additional information regarding the Company's plans and future prospects.
Knowledge; Access. Seller has been provided access to such ----------------- information regarding the Common Stock, the Buyer, and the Buyer's assets, financial condition and business prospects, including access to executive officers of the Buyer, as it deems necessary to the making of an informed decision to sell the Shares as contemplated herein. Seller is a sophisticated investor with extensive experience in purchase and sale of securities and in the conduct of businesses similar to that of the Buyer.
Knowledge; Access. 21 10.7 Brokers . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 21
Knowledge; Access. Merger Corp represents that it has such knowledge and experience in financial and business matters as to be capable of evaluating the merits and risks of its execution and delivery of the Merger Corp Delivered Documents and the consummation of the transactions contemplated thereby. Merger Corp further represents that it has had access to, and prior to its execution of this Agreement, the opportunity to ask questions of, and receive answers from, the Company and its respective officers concerning the terms and conditions of the transactions contemplated hereby and to obtain additional information (to the extent that the Company possessed such information (or could acquire it without unreasonable effort or expense) necessary to verify the accuracy of any information furnished to it or to which it had access.
Knowledge; Access. The Original Agreement is hereby amended by adding a new Section 2.3 which shall read as follows:
Knowledge; Access. As soon as practicable following the Amendment Date, subject to the confidentiality obligations set forth in Section 7.4, Novartis shall (and shall cause its Affiliates to) provide Array with copies of or reasonable access to all information, personnel, documentation, materials and other resources regarding Binimetinib and the Transferred Assets reasonably necessary or otherwise reasonably requested by Array, to (a) enable Array to effectively engage, negotiate with, and execute a collaboration and license agreement(s) (collectively, the “Alliance Agreement”) with a Third Party (as defined in the EC Commitments, the [*] Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. Confidential treatment has been requested with respect to this information. “Suitable Partner”) governing the research, development, manufacture, sale, marketing, distribution and commercialization of Binimetinib and products containing Binimetinib in the EEA and in any jurisdictions where the applicable antitrust authorities have required that Array enter into such collaboration or license agreement; and (b) subject to customary and reasonable confidentiality and non-use arrangements, provide any potential Suitable Partner with reasonable diligence regarding the research, development, manufacture, sale, marketing, distribution and commercialization of Binimetinib and products containing Binimetinib in the EEA and such additional jurisdictions; provided, however that Array shall not be permitted to so execute an Alliance Agreement or so provide any potential Suitable Partner with any such diligence information that constitutes the Confidential Information of Novartis prior to the adoption of the EC Remedy Decisions.”
Knowledge; Access. Such Selling Investor represents that it has such knowledge and experience in financial and business matters as to be capable of evaluating the merits and risks of its execution and delivery of this Agreement and the other documents being executed and delivered by such Selling Investor pursuant hereto and the consummation of the transactions contemplated hereby and thereby. Such Selling Investor further represents that it has had access to, and prior to its execution of this Agreement, the opportunity to ask questions of, and receive answers from, the Company and the Partnership and their respective officers concerning the terms and conditions of the transactions contemplated hereby and to obtain additional information (to the extent that either the Company or the Partnership possessed such information (or could acquire it without unreasonable effort or expense) necessary to verify the accuracy of any information furnished to it or to which it had access.
Knowledge; Access. As soon as practicable following the date hereof, subject to the confidentiality obligations set forth in Section 7.4, Novartis shall (and shall cause its Affiliates to) provide Array with copies of or reasonable access to all information, personnel, documentation, materials and other resources regarding Encorafenib and the Transferred Assets reasonably necessary or otherwise reasonably requested by Array, to (a) enable Array to effectively engage, negotiate with, and execute a collaboration and license agreement(s) (collectively, the “Alliance Agreement”) with a Suitable Partner governing the research, development, manufacture, sale, marketing, distribution and commercialization of Encorafenib and products containing Encorafenib in the EEA and in any additional jurisdictions where the applicable antitrust authorities have required that Array enter into such collaboration or license agreement; and (b) subject to customary and reasonable confidentiality and non-use arrangements, provide any potential Suitable Partner with reasonable diligence regarding the research, development, manufacture, sale, marketing, distribution and commercialization of Encorafenib and products containing Encorafenib in the EEA and such additional jurisdictions; provided, however that Array shall not be permitted to so execute an Alliance Agreement or so provide any potential Suitable Partner with any such diligence information that constitutes the Confidential Information of Novartis prior to the adoption of the EC Remedy Decisions.
Knowledge; Access. Such Stockholder represents that it has such knowledge and experience in financial and business matters as to be capable of evaluating the merits and risks of its execution and delivery of this Agreement and the other Stockholder Delivered Agreements and the consummation of the transactions contemplated hereby and thereby. Such Stockholder further represents that it has had access to, prior to its execution of this Agreement, the opportunity to ask questions of, and receive answers from, the Company and the Partnership and their respective officers concerning the terms and conditions of the transactions contemplated hereby and to obtain additional information (to the extent the either the Company or the Partnership possessed such information (or could acquire it without unreasonable effort or expense) necessary to verify the accuracy of any information furnished to it or to which it had access.
